Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revestive in Pediatric Short Bowel Syndrome (REVE)
NCT03562130Phase 4Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2018
- Primary completion
- Dec 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of teduglutide in short bowel syndrome (SBS), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Decrease in parenteral nutrition: Parenteral Nutrition/Resting Energy Expenditure at 24 weeks. Started Jul 2018; status: completed.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT03562130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03562130.